Literature DB >> 16603864

Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

Carmen de Mendoza1, Luisa Valer, Lee Bacheler, Theresa Pattery, Angélica Corral, Vincent Soriano.   

Abstract

Mutation proI47A has recently been associated with lopinavir/ritonavir (LPV/r) resistance. Only four out of 1859 specimens (0.2%) sent for drug resistance testing (219 drug-naive and 1650 antiretroviral-experienced) showed I47A. All belonged to patients failing LPV/r. The prevalence among protease inhibitor-experienced patients was 0.6%. Phenotypic testing showed that proI47A caused high-level lopinavir resistance (> 100-fold) and cross-resistance to amprenavir, whereas it caused hypersusceptibility to saquinavir. ProI47A should thus be considered the primary lopinavir resistance mutation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16603864     DOI： 10.1097/01.aids.0000222084.44411.cc

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  8 in total

1.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

2.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Martin Lepsík; Jirí Brynda; Pavlína Rezácová; Jana Václavíková; Ron M Kagan; Ladislav Machala; Jan Konvalinka
Journal:  Protein Sci       Date:  2008-06-17       Impact factor: 6.725

4.  Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

Authors:  Esmeralda A Soares; André F Santos; Luis M Gonzalez; Matthew S Lalonde; Denis M Tebit; Amilcar Tanuri; Eric J Arts; Marcelo A Soares
Journal:  J Antimicrob Chemother       Date:  2009-08-26       Impact factor: 5.790

5.  The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Authors:  Frank Wiesmann; Jan Vachta; Robert Ehret; Hauke Walter; Rolf Kaiser; Martin Stürmer; André Tappe; Martin Däumer; Thomas Berg; Gudrun Naeth; Patrick Braun; Heribert Knechten
Journal:  AIDS Res Ther       Date:  2011-02-13       Impact factor: 2.250

6.  Current and Novel Inhibitors of HIV Protease.

Authors:  Jana Pokorná; Ladislav Machala; Pavlína Rezáčová; Jan Konvalinka
Journal:  Viruses       Date:  2009-12-11       Impact factor: 5.048

7.  The Geogenomic Mutational Atlas of Pathogens (GoMAP) web system.

Authors:  David P Sargeant; Michael W Hedden; Sandeep Deverasetty; Christy L Strong; Izua J Alaniz; Alexandria N Bartlett; Nicholas R Brandon; Steven B Brooks; Frederick A Brown; Flaviona Bufi; Monika Chakarova; Roxanne P David; Karlyn M Dobritch; Horacio P Guerra; Kelvy S Levit; Kiran R Mathew; Ray Matti; Dorothea Q Maza; Sabyasachy Mistry; Nemanja Novakovic; Austin Pomerantz; Timothy F Rafalski; Viraj Rathnayake; Noura Rezapour; Christian A Ross; Steve G Schooler; Sarah Songao; Sean L Tuggle; Helen J Wing; Sandy Yousif; Martin R Schiller
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

8.  Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

Authors:  Soo-Yon Rhee; Philip L Tzou; Robert W Shafer
Journal:  Viruses       Date:  2021-05-11       Impact factor: 5.048
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.